Robert Ferris, MD, PhD | Authors

Articles

Unique Immunotherapy Combinations Come to the Forefront at SITC Meeting

January 27, 2021

In this trial, the previous observation of liver toxicity using CD137 agonism was not observed, suggesting a safe neoadjuvant dosing. Indeed, 30% of patients demonstrated pathologic responses. Further research may combine a way of overcoming immune checkpoint pathways with stimulatory agonists.